TSP is a reliable marker of clinical outcome measures, including platinum chemoresistance, PFS, and OS, in high-grade serous ovarian cancer.
Back
Prognostic Study Correlates TSP and Clinical Outcomes in Ovarian Cancer
Emil Lou, MD, PhD, FACP, discusses data from a study evaluating whether tumor-stroma proportion can predict chemoresistance and other outcomes in patients with ovarian cancer.
Prognostic Study Correlates TSP and Clinical Outcomes in Ovarian Cancer
Episodes
All
All
Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.
Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic use of tumor stroma proportion for outcomes and chemoresistance in ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026
5